personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Comparison of intravitreal bevacizumab and ranibizumab treatment for contralateral diabetic macular edema

Session Details

Session Title: Vascular Diseases & Anterior/posterior segment surgery

Session Date/Time: Sunday 29/09/2013 | 11:00-13:00

Paper Time: 12:04

Venue: Hall 3 (Level 0)

First Author: B.Bakbak TURKEY

Co Author(s):    B. Turgut Ozturk   S. Gonul   S. Gedik   -. -     

Abstract Details

Purpose:

To aim of this study was to compare the effects of bevacizumab and ranibizumab on visual function and macular thickness in the contralateral eye of the same patients with bilateral diabetic macular edema (DME).

Setting:

Thirty-one diabetic patients who had been followed up for DME at Selcuk University, Department of Ophthalmology

Methods:

Diabetic patients who had been followed up for DME at Selcuk University, Department of Ophthalmology and treated with both bevacizumab and ranibizumab for DME were considered for enrollment. Those patients who received laser treatment between injections were excluded. The best correct visual acuity (BCVA) assessment with Early Treatment Diabetic Retinopathy Study (ETDRS) chart and central subfield macular thickness (CSMT) measurement using optical coherence tomography-3 of the contralateral uninjected eyes before and 4 weeks after injections were recorded as outcome measures.

Results:

The study included 31 eyes of 31 patients with a mean age of 58.7 ± 11.37 years. The median BCVA of the uninjected fellow eye was 49 ETDRS letters and the median CSMT was 451 μm preceding the bevacizumab injection. At the 4th week control after the injection, median BCVA increased to 51 ETDRS letters (P=0.107) and the median CSMT decreased to 398 μm (P=0.042). The mean interval between bevacizumab and ranibizumab treatment was 4.68 ± 1.47 months. The measurements on the untreated fellow eye after ranibizumab treatment showed that the median BCVA decreased from 56 to 53 ETDRS letters and the median CSMT increased from 375 μm to a level of 412 μm. The change in BCVA and CSMT was found to be statistically insignificant (P=0.134, P=0.146, respectively).

Conclusions:

Our comparison of the effect of both bevacizumab and ranibizumab therapies on the fellow eye of the same patients demonstrated d that in contrast to ranibizumab, intravitreal administration of bevacizumab resulted with a statistically significant decrease in macular thickness in the untreated eye, in patients with bilateral DME.This finding suggested the systemic penetrationof bevacizumab in the diabetic human eye.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy